Case Study: Star Anise

Plant-derived Ingredients and Synthetic Biology

This case study illustrates how a key pharmaceutical ingredient, shikimic acid – traditionally derived from star anise cultivated by Chinese farmers – can be rapidly replaced by a new technological production process. Using synthetic biology, shikimic acid is now being produced commercially in drug industry fermentation tanks. The transition took less than a decade. Shikimic acid is just one example of a raw material that may be affected; it is conservatively estimated that at least 50% of today’s commercial pharmaceutical compounds are derived from plants, animals and microorganisms. No inter-governmental body is addressing the potential impacts of synthetic biology on the conservation and use of biodiversity and on the livelihoods of those who depend on agricultural export commodities (including high-value flavors, fragrances, essential oils, etc). The Convention on Biological Diversity is the most appropriate forum to address this new and emerging issue. 

 

AttachmentSize
PDF icon Final_CBD_Star Anise_case_study_TA.pdf370.63 KB

Please consider supporting ETC's unique research and advocacy with a tax-deductibe donation. Donate here